Hologic, Inc. (HOLX)

Market Cap	14.20B
Revenue (ttm)	4.04B
Net Income (ttm)	744.00M
Shares Out	224.39M
EPS (ttm)	3.16
PE Ratio	20.05
Forward PE	14.57
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,788,483
Open	63.23
Previous Close	63.39
Day's Range	62.98 - 63.92
52-Week Range	62.70 - 84.67
Beta	0.97
Analysts	Buy
Price Target	85.42 (+35.01%)
Earnings Date	Feb 5, 2025

About HOLX

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginos...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jun 21, 1990
• Employees: 6,990
• Stock Exchange: NASDAQ
• Ticker Symbol: HOLX
• Website: https://www.hologic.com

Financial Performance

In 2024, Hologic's revenue was $4.03 billion, a decrease of -0.00% compared to the previous year's $4.03 billion. Earnings were $789.50 million, an increase of 73.14%.

Analyst Forecast

According to 14 analysts, the average rating for HOLX stock is "Buy." The 12-month stock price forecast is $85.42, which is an increase of 35.01% from the latest price.

Price Target

$85.42

(35.01% upside)

Analyst Consensus: Buy